2002. ACCENT I

Phase 3 / IFX/ CD/Maintenance

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

Patients with moderate-severe CD, CDAI>220 received 5mg/kg 1st dose of IFX.

At w2 after assessment of response randomized to different groups: <u>Group I</u>: placebo. <u>Group II</u>: IFX 5 mg/kg weeks 2,6 and q8w. <u>Group III</u>: IFX 10mg/kg maintenance q8w.

The prespecified <u>co-primary endpoints</u>:

- Response at w2 & remission (CDAI <150) at w30.
- -Time to loss of response up to week 54 in patients who responded.
- Analyses of the co-primary endpoints were by intention to treat.

Results:

- w2: **58% responded** to single IFX infusion.
- **w30 remission**: 21% pbo vs 39% IFX5 vs 45% IFX10; p=0.003, p=0.0002.
- Median time to loss of response in IFX5 and IFX10 was 38w.

Conclusion:

Induction and maintenance response to IFX q8w better than placebo in CD.




Figure 2: Clinical response and clinical remission for week-2 responders

Sinical response-reduction in CDAI to >70 points and >256 from baseline. Clinical remission-CDAI <150 points

H